Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy

Phytotherapy Research

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Piotrowska, Ewa ^a   Jakóbkiewicz Banecka, Joanna ^a   Wȩgrzyn, Grzegorz ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

Gene expression targeted isoflavone therapy; Isoflavones; Mucopolysaccharidoses; Sanfilippo disease; Soy isoflavone extracts; Substrate reduction therapy

Indexed keywords

ACETYL BETA GLYCOSIDE DAIDZEIN; ACETYL BETA GLYCOSIDE GENISTEIN; ACETYL BETA GLYCOSIDE GLYCITEIN; DAIDZEIN; DAIDZIN; GENISTEIN; GENISTIN; GLYCITEIN; GLYCITIN; GLYCOSAMINOGLYCAN; ISOFLAVONE DERIVATIVE; MALONYL BETA GLYCOSIDE DAIDZEIN; MALONYL BETA GLYCOSIDE GENISTEIN; MALONYL BETA GLYCOSIDE GLYCITEIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DETERMINATION; FIBROBLAST; GLYCOSAMINOGLYCAN METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PHYTOTHERAPY; SANFILIPPO SYNDROME; SOYBEAN; TABLET FORMULATION;

CELL LINE; DIETARY SUPPLEMENTS; DOSAGE FORMS; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; PLANT EXTRACTS; SOYBEANS;

EID: 75749099273     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2944     Document Type: Article

References (23)

1. Beck M. 2007a. Mucopolysaccharidoses: clinical features and management. In Genetic Metabolic Disorders: Management, Costs and Sociomedical Aspects, vom Dahl S, Wendel U, Strohmeyer G (eds). Deutscher Arzte-Verlag: Cologne, 13-18.
2. Beck M. 2007b. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121: 1-22.
3. Chua R, Anderson K, Chen J, Hu M. 2004. Quality, labeling accuracy, and cost comparison of purified soy isoflavonoid products. J Altern Complement Med 10: 1053-1060.
4. Chun J, Kim GM, Lee KW et al. 2007. Conversion of isoflavone glucosides to aglycones in soymilk by fermentation with lactic acid bacteria. J Food Sci 72: M39-M44.
5. Hulem R, Blair RM. 2006. Soy isoflavones for postmenopausal symptoms. An examination of evidence. Adv Nurse Pract 14: 32-38.
6. Hur HG, Lay JO Jr, Beger RD, Freeman JP, Rafii F. 2000. Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch Microbiol 174: 422-428.
7. Jackman KA, Woodman OL, Sobey CG. 2007. Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. Curr Med Chem 14: 2824-2830.
8. Jakóbkiewicz-Banecka J, Piotrowska E, Narajczyk, M, Barańska S, Wȩgrzyn G. 2009. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16: 26.
9. Jakóbkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. 2007. Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 48: 383-388.
10. Kerem E. 2006. Mutation specific therapy in CF. Paediatr Respir Rev 7 (Suppl 1): S166-S169.
11. Klein CB, King AA. 2007. Genistein genotoxicity: critical considerations of in vitro exposure dose. Appl Pharmacol 224: 1-11.
12. Marotti I, Bonetti A, Biavati B, Catizone P, Dinelli G. 2007. Biotransformation of common bean (Phaseolus vulgaris L.) flavonoid glycosides by bifidobacterium species from human intestinal origin. J Agric Food Chem 55: 3913-3919.
13. Neufeld EF, Muenzer J. 2001. The mucopolysaccharidoses. In The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaud et al., Sly WS, Valle D (eds). McGraw-Hill: New York, 3421-3452.
14. Piotrowska E, Jakóbkiewicz-Banecka J, Barańska S et al. 2006. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14: 846-852.
15. Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A et al. 2008. Genistin-rich isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 69: 166-179.
16. Sarkar FH, Adsule S, Padhye S, Kulkarni S, Li Y. 2006. The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 6: 401-407.
17. Sarkar FH, Li Y. 2006. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66: 3347-3350.
18. Schmidt A, Hughes LK, Cai Z et al. 2008. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol 153: 1311-1323.
19. Setchell KDR, Brown NM, Desai P et al. 2001. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 131: S1362-S1375.
20. Si H, Liu D. 2007. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem 14: 2581-2589.
21. Szkudelska K, Nogowski L. 2007. Genistein - a dietary compound inducing hormonal and metabolic changes. J Steroid Biochem Mol Biol 105: 37-45.
22. Von Löw EC, Perabo FG, Siener R, Müller SC. 2007. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 21: 189-204.
23. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. 2006. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 13: 831-839.